Age Tech World explores the latest business developments in the world of ageing and longevity.
Klotho Neurosciences to expand development programmes beyond neurology
Klotho Neurosciences has announced that it is evaluating the acquisition of several complementary technologies aimed at supporting healthy brain function, organ health, and longevity.
In addition to its core programmes targeting brain ageing and neurodegenerative diseases such as ALS, Alzheimer’s, and Parkinson’s, Klotho will now be seeking to expand into adjacent technologies that complement its proprietary anti-ageing Klotho platform.
The goal is to slow biological ageing and reduce the burden of age-related diseases, ultimately promoting a longer, healthier life.
“As announced previously, we’ve begun manufacturing and development of KLTO-101 and KLTO-202,” said Klotho CEO Dr. Joseph Sinkule.
We’re also exploring other treatments that could support healthy ageing and extend human longevity.
The human Klotho gene is strongly linked to ageing and longevity. Klotho levels decline with age, contributing to age-related disorders such as cardiometabolic disease, neurodegeneration, cancer, sarcopenia (muscle wasting), osteoporosis, and general fatigue. Silencing of the Klotho gene has been shown to accelerate multi-organ deterioration.
“The Klotho gene is what we call a master gene,” stated Shalom Hirschman, physician and senior consultant at Klotho.
“The Klotho gene has pleotropic actions modulating many critical cellular pathways including insulin resistance, insulin-like growth factor-1, FOXO3 transcription factors, and Wnt signaling pathways leading to the reduction of inflammatory and mitochondrial oxidative stresses and other cell-damaging mechanisms that can be prevented by two alpha-Klotho protein isoforms – soluble Klotho and secreted-Klotho.”
“We’re assembling a team of scientists, clinicians, and business leaders focused on identifying key longevity indicators,” said Jeffrey LeBlanc, Klotho CFO.
“This includes evaluating genes and proteins such as alpha-Klotho, beta-Klotho, FOXO3, anti-myostatin, and their isoforms.”
Circulate Health raises US$12m in seed funding
Circulate Health, a longevity startup working to harness the potential of therapeutic plasma exchange (TPE) to advance human healthspan and lifespan, had raised US$12m.
The funds were raised in a seed funding round led by Khosla Ventures, with participation from Seaside Ventures and CSC Ventures.
The financing follows the release of Circulate’s trial study, the first of its kind to demonstrate the effectiveness of TPE in improving healthspan and reducing biological age
TPE is a patented method of therapeutic plasma exchange that uses a procedure that separates, removes, and replaces a patient’s plasma to treat inflammation, improve healthspan, and address certain chronic diseases.
Circulate has been operating in stealth for the past three years, studying the benefits of TPE and its ability to improve human healthspan and address the hallmarks of again, while partnering with clinics to deliver TPE across the US and soon internationally.
Everlab raises US$10M for AI-powered preventive healthcare
AI powered health platform Everlab has raised US$10 million (AU$15 million) to accelerate its international expansion, fuel the development of its proprietary AI healthtech platform, and support the rollout of an integrated product ecosystem designed to deliver proactive care.
Everlab aims to address the gap in chronic disease care with a tiered membership model that combines advanced diagnostics, digital-first doctor consultations, and intelligent health insights to deliver personalised health prevention.
Members have access to comprehensive screening services, including advanced blood testing, whole-body MRIs, DEXA scans, VO2 max, ECG, isometric strength, continuous glucose monitoring, food journal analysis, and CT coronary angiograms paired with continuous support and personalised prevention plans.
Everlab’s offering is underpinned by its full-stack clinical platform: a suite of AI agents that ingest, analyze, and interpret complex health data.
According to the company, these agents automate clinical summaries, identify early risk markers, and recommend personalised next steps, freeing physicians from administrative overhead and enabling earlier, more precise interventions.
“We believe everyone deserves access to world-class preventive care,” said Marc Hermann, Founder and CEO of Everlab.
“By combining AI with the knowledge of leading clinicians, we’ve built a new kind of health platform designed to deliver smarter, earlier care to millions.”
Donanemab receives positive opinion from CHMP in early symptomatic Alzheimer’s disease
Eli Lilly has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending donanemab for the treatment of early symptomatic Alzheimer’s disease in adults with confirmed amyloid pathology who are apolipoprotein E ε4 (ApoE4) heterozygotes or non-carriers.
The European Commission is expected to make a regulatory decision on donanemab in the coming months.
The positive opinion was primarily based on clinical trial data from the TRAILBLAZER-ALZ 2 clinical trial demonstrating that donanemab significantly slowed cognitive and functional decline and reduced the risk of progressing to the next clinical stage of disease.
It was also based on data from the TRAILBLAZER-ALZ 6 clinical trial which evaluated a modified titration dosing schedule.
In the TRAILBLAZER-ALZ 6 study, the modified titration schedule significantly lowered the incidence of amyloid-related imaging abnormalities with edema/effusion (ARIA-E) versus the dosing schedule used in TRAILBLAZER-ALZ 2 at 24 and 52 weeks, while still achieving similar levels of amyloid plaque removal and P-tau217 reduction.
“This positive opinion marks a significant milestone in our efforts to bring donanemab to eligible patients across Europe,” said Patrik Jonsson, executive vice president and president of Lilly International.
“Donanemab has the potential to make a meaningful difference for people living with early symptomatic Alzheimer’s disease, and Lilly remains committed to advancing the science through ongoing clinical trials and programmes.”
Johnson & Johnson showcases latest advancements in Alzheimer’s research
Johnson & Johnson (J&J) has announced that new data from its Alzheimer’s disease (AD) research programme will be presented at the Alzheimer’s Association International Conference (AAIC), from July 27 to 31 in Toronto, Canada.
Across 12 abstracts, J&J will share insight into how tau impacts brain function in early AD and reinforce the predictive strength of plasma biomarker pTau217 for tracking cognitive decline in at-risk individuals.
The company will also introduce findings from the Global Neurodegeneration Proteomics Consortium (GNPC), a public-private partnership co-founded by Johnson & Johnson and Gates Ventures, the private office of Bill Gates.
“Long-standing challenges in assembling large, diverse datasets have made progress in understanding the biology of neurodegenerative diseases extremely slow. At AAIC, we are sharing how the GNPC is enabling discovery at scale,” said Niranjan Bose, managing director of health and life sciences at Gates Ventures.
“Even at this early stage, researchers are uncovering new insights into some of the most studied risk factors, highlighting the power of the GNPC to drive discovery, reveal new targets, and ultimately accelerate progress for the more than 57 million people living with Alzheimer’s disease and other dementias worldwide.”